GlassScriptPhysician profile
Mario J Lopez
NPI 1710990882
$10,375.84
in general payments reported to CMS, 2019-2025
43 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,408 · 2020: $979 · 2021: $805 · 2022: $994 · 2023: $1,596 · 2024: $2,423 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,872 · Debt Forgiveness: $216 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,871.65 |
| Debt Forgiveness | $216.47 |
| Education | $101.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $844.23 | 2019-2025 | Aveir, Jot Dx, Triclip |
| Philips North America LLC | $710.04 | 2020-2025 | (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und, Extended Holter |
| Boston Scientific Corporation | $706.55 | 2019-2025 | Watchman Flx, Farapulse, Lux-Dx Insertable Cardiac Monitor |
| Novartis Pharmaceuticals Corporation | $644.65 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $637.43 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $617.93 | 2023-2025 | |
| Amgen INC. | $599.33 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $483.52 | 2021-2025 | Verquvo |
| Esperion Therapeutics, INC. | $441.94 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $393.58 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $380.14 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $379.79 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $352.20 | 2019-2023 | |
| Pfizer INC. | $320.53 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $276.51 | 2020-2025 | Lifevest |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $256.20 | 2023-2024 | Inpefa |
| Cvrx, INC. | $227.36 | 2022-2025 | Barostim Neo System |
| Abiomed | $227.11 | 2024 | Impella |
| Astellas Pharma US INC | $226.25 | 2019-2022 | |
| Scpharmaceuticals INC. | $222.51 | 2023-2025 | |
| Merit Medical Systems INC | $216.47 | 2025 | |
| Heartflow, INC. | $150.78 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $143.61 | 2024 | Opsumit, Uptravi |
| Atricure, INC. | $135.50 | 2022-2024 | |
| Novo Nordisk INC | $116.00 | 2021-2025 | Wegovy, Ozempic |
| Regeneron Healthcare Solutions, INC. | $111.25 | 2019-2023 | Evkeeza |
| Kestra Medical Technology Services, INC. | $100.06 | 2023-2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $70.98 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $58.88 | 2023 | Amvuttra |
| Impulse Dynamics (USA) INC. | $45.02 | 2023 | Optimizer |
| Irhythm Technologies, INC. | $41.89 | 2022-2023 | Zio Xt Patch |
| Medtronic, INC. | $39.72 | 2023-2024 | Reveal Linq, Micra |
| Kiniksa Pharmaceuticals International, Plc | $30.73 | 2024 | Arcalyst |
| Cashflow Solutions, LLC | $27.65 | 2023-2025 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Bardy Diagnostics, INC. | $25.00 | 2020 | |
| Aegerion Pharmaceuticals, INC. | $23.95 | 2019 | |
| Lundbeck LLC | $19.41 | 2020 | |
| Cardiofocus, INC. | $16.35 | 2019 | |
| Antares Pharma, INC. | $15.86 | 2022 | |
| Terumo Medical Corporation | $13.25 | 2019 | |
| Ge Healthcare | $12.96 | 2023 | |
| Medtronic Vascular, INC. | $12.72 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.